Kineta (KA) Stock Price, News & Analysis

Company Overview

Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Seattle, Washington.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.57 to $0.86
• 52-Week Range: N/A
• Volume: 530,700 shs
• Average Volume: 409,478 shs
• Market Capitalization: $7.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Buy

Kineta Stock Analysis - MarketRank™

Kineta scored higher than 27% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Kineta has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Kineta has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Kineta is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kineta is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for KA.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kineta does not currently pay a dividend.

Dividend Growth

Kineta does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for KA.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

2 people have searched for KA on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kineta insiders have not sold or bought any company stock.

Percentage Held by Insiders

23.70% of the stock of Kineta is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 30.32% of the stock of Kineta is held by institutions.

KA Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Kineta own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kineta investors own include Intel (INTC), Motley Fool 100 Index ETF (TMFC), Argan (AGX), AST SpaceMobile (ASTS), AutoZone (AZO), Cadence Design Systems (CDNS) and Walt Disney (DIS).

Company Calendar

• Today: 11/24/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KA
• CUSIP: N/A
• CIK: 1445283
• Web: www.kinetabio.com
• Phone: (206) 378-0400
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $8.00
• High Stock Price Target: $8.00
• Low Stock Price Target: $8.00
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-14,100,000.00
• Net Margins: N/A
• Pretax Margin: -345.77%
• Return on Equity: -1,044.95%
• Return on Assets: -336.46%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 0.14
• Quick Ratio: 0.14

Sales & Book Value

• Annual Sales: $5.44 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.29 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 12,254,000
• Free Float: 9,350,000
• Market Cap: $7.04 million
• Optionable: Not Optionable
• Beta: 0.46